ArticlePhysiological reports2025
Targeting glial activation to mitigate mirror-image and extraterritorial neuropathic pain in a CCI model of neuropathic pain in male rats.
Article in Physiological reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting glial activation to mitigate mirror-image and extraterritorial neuropathic pain in a CCI model of neuropathic pain in male rats.Physiological reports · 2025Article
- Oxaliplatin-induced neuropathic pain in cancer: animal models and related research progress.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neuropathic pain (NP) arises from nerve damage or compression and often extends to the contralateral side of the body (mirror-image pain, MP) and adjacent non-injured areas (extraterritorial pain). This study investigates whether altered sensitivity in these contralateral and peripheral regions is mediated by glial cells, using the chronic constriction injury (CCI) model of NP. Thirty-two male Wistar rats were randomly assigned into four groups (8/group): sham, CCI + vehicle, CCI + minocycline (MIN;10 mg/kg), and CCI + pentoxifylline (PTX;8 mg/kg). The CCI model was employed for NP induction. MIN and PTX were administered intraperitoneally from postoperative days (POD)4 to POD14, once daily. Pain responses were assessed on POD0, 2, 6, 10, and14 using Hargreaves, von Frey, and Tail-flick tests. Western blot analysis was performed on POD14 to measure Iba1 and GFAP protein expression in the spinal cord hemispheres. Results revealed that post-injury treatment with MIN and PTX significantly reduced contralateral thermal hyperalgesia, mechanical allodynia, and tail-flick responses. Correspondingly, the contralateral spinal cord exhibited significantly decreased GFAP and Iba1 protein expression compared to the CCI + vehicle treated group. These findings suggest that post-injury glial cell inhibition effectively mitigates neuropathic pain and prevents the development of MP and extraterritorial pain. This highlights the potential for clinical applications targeting glial cells to manage NP even after nerve injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.